On October 1, Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE) reported results from their phase 3 clinical trial of ECELON-2. The trial demonstrated a statistically significant improvement in progression-free survival for patients using their drug Adcentris in combination with chemotherapy when compared to chemotherapy alone. It is the first randomized Phase 3 […]
On September 24, Kirkland’s, Inc. (KIRK) announced that its Board of Directors authorized a new share repurchase program. The new program allows the company to repurchase up to $10 million worth of common shares. Kirkland’s still has $2.9 million available from its previous $10 million share repurchase program. Sonal alerted subscribers of the event […]
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (IONS), announced positive topline clinical trial results on September 24. The Phase 2 clinical trial is studying the effect of AKCEA-APO(a)-LRx on patients with established cardiovascular disease and elevated levels of lipoprotein(a), known as Lp(a). The goal of the Phase 2 clinical study was to […]
On September 13, Progenics Pharmaceutical, Inc. (PGNX) reported Phase 3 clinical trial results from its study of 1404, the company’s prostate specific membrane antigen (PSMA). It is a targeted small molecule SPECT/CT imaging agent designed to visualize prostate cancer. The results met one of the co-primary endpoints of identifying patients without clinically significant prostate cancer. […]
On September 5, ProQR Therapeutics, N.V. (PRQR) announced positive results from its Phase 1/2 trial of QR-110 in patients with Leber’s congenital amaurosis 10 (LCA 10) due to a mutation in the CEP290 gene. LCA10 usually leads to childhood blindness and currently has no available treatment options. Patients in the trial had rapid and sustained […]
The August 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide
INSYS Therapeutics, Inc. (INSY) announced on August 30 that the company received a Fast Track from the FDA for the company’s epinephrine nasal spray. The spray is an investigational drug for the treatment of anaphylaxis, a life-threatening allergic reaction requiring urgent treatment. INSYS is a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids […]
On August 21, Analog Devices, Inc. (ADI) announced that the company’s Board of Directors voted to reinstate their share repurchase program. The company’s existing share repurchase program started in 2004, and Analog Devices has repurchased $5.4 billion in stock since that time. This reinstatement increases the total authorization by an additional $2 billion. At […]
The July 2018 scorecard for the signals generated from Sonal can be downloaded here. For more information regarding how you can trade these signals, see the article The Three Moves for Event Based Trading Try Sonal 30 days for free and cancel anytime! Subscribe here and check out the Quickstart Guide
On August 16, Hemisphere Media Group, Inc. (HMTV) announced that its Board of Directors has authorized a new $25 million share repurchase program. The new share repurchase authorization is an addition to the company’s existing $25 million share repurchase program. Hemisphere Media Group is the only U.S. media company solely focusing on the U.S. Hispanic […]
China Rapid Finance Limited (XRF) announced on August 15 that its Board of Directors authorized a new share repurchase program. Under the program, the company can repurchase up to $20 million of its ordinary shares in the form of American depository shares. China Rapid Finance is one of China’s largest consumer lending marketplaces. Sonal […]
Let us send you a summary of the signals Sonal generates EVERY WEEK… and you can decide if you’re missing anything.